Innophos Holdings (Innophos Holdings) Risk Assessment

View and export this data going back to 2006. Start your Free Trial

What is Innophos Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Innophos Holdings is: No Data: Cannot be evaluated.

Competitive Comparison of Innophos Holdings's Risk Assessment

For the Specialty Chemicals subindustry, Innophos Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innophos Holdings's Risk Assessment Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Innophos Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Innophos Holdings's Risk Assessment falls into.

Innophos Holdings (NAS:IPHS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Innophos Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Innophos Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Innophos Holdings (Innophos Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Innophos Holdings Inc (NAS:IPHS) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

259 Prospect Plains Road, Cranbury, NJ, USA, 08512

Website

http://www.innophos.com

Innophos Holdings Inc is a holding company that manufactures and sells through its subsidiaries a variety of ingredients used in the production of food, beverages, dietary supplements, pharmaceuticals, and oral care products. Innophos ingredients are made primarily from specialty phosphates. The company organizes itself into three segments namely Food, Health and Nutrition; Industrial Specialties and Other. The Food, Health and Nutrition segment contribute the maximum revenue. The company operates in U.S., Canada, Mexico and other countries.

Executives

John M Steitz	director	ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
Kim Ann Mink	director, officer: Chairman, CEO, President	259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Gary A Cappeline	director	50 E RIVERCENTER BLVD, COVINGTON KY 41012
Karen R Osar	director	C/O WESTVACO CORP, ONE HIGH RIDGE PARK, STAMFORD CT 06905
Mark Santangelo	officer: Sr. VP, Mfg, Eng & EH&S	15710 JOHN F. KENNEDY BLVD., SUITE 300 HOUSTON TX 77032
Peter T Thomas	director	1000 LAKESIDE AVENUE, CLEVELAND OH 44114
Hermanus Kieftenbeld	officer: Senior VP and CFO	259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
James P. Zallie	director	5 WESTBROOK CORPORATE CENTER, WESTCHESTER IL 60154
Randy Gress	director, officer: CEO	259 PROSPECT PLAINS ROAD, P O BOX 8000, CRANBURY NJ 08512-8000
Stephen M Zide	director	BAIN CAPITAL PARTNERS, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Richard Heyse	officer: VP-Chief Financial Officer	259 PROSPECT PLAINS ROAD, BUILDING G, P O BOX 8000, CRANBURY NJ 08512-8000
Bain Capital Investors Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Partners Vii Lp	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Llc	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Lp	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116